The emergence of the Middle East respiratory syndrome coronavirus - PubMed (original) (raw)

Review

The emergence of the Middle East respiratory syndrome coronavirus

Shauna Milne-Price et al. Pathog Dis. 2014 Jul.

Abstract

On September 20, 2012, a Saudi Arabian physician reported the isolation of a novel coronavirus from a patient with pneumonia on ProMED-mail. Within a few days, the same virus was detected in a Qatari patient receiving intensive care in a London hospital, a situation reminiscent of the role air travel played in the spread of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002. SARS-CoV originated in China's Guangdong Province and affected more than 8000 patients in 26 countries before it was contained 6 months later. Over a year after the emergence of this novel coronavirus--Middle East respiratory syndrome coronavirus (MERS-CoV)--it has caused 178 laboratory-confirmed cases and 76 deaths. The emergence of a second highly pathogenic coronavirus within a decade highlights the importance of a coordinated global response incorporating reservoir surveillance, high-containment capacity with fundamental and applied research programs, and dependable communication pathways to ensure outbreak containment. Here, we review the current state of knowledge on the epidemiology, ecology, molecular biology, clinical features, and intervention strategies of the novel coronavirus, MERS-CoV.

Keywords: MERS-CoV; coronavirus; epidemiology; intervention strategies; molecular biology.

Published 2014. This article is a US Government work and is in the public domain in the USA.

PubMed Disclaimer

Figures

Figure 1

Figure 1

False‐color

MERS

‐

C

o

V

particle visualized by electron microscopy. A

MERS

‐

C

o

V

particle (yellow) attached to the surface of a cell (red). The characteristic

MERS

‐

C

o

V

spike glycoproteins are clearly visible on the surface of the

MERS

‐

C

o

V

particle.

Figure 2

Figure 2

Geographic distribution of the

MERS

‐CoV outbreak. The geographic distribution of

MERS

‐

C

o

V

cases up to February 1, 2014 is shown. Travel history of cases imported outside of the Arabian Peninsula is indicated with dotted arrows. Countries with primary

MERS

‐

C

o

V

cases are shown in brown, countries with imported

MERS

‐

C

o

V

cases and no confirmed human‐to‐human transmission are shown in pink, and countries with imported

MERS

‐

C

o

V

cases and subsequent human‐to‐human transmission are shown in green.

Figure 3

Figure 3

Timeline of the

MERS

‐

C

o

V

outbreak. Temporal distribution of

MERS

‐CoV cases from March 2012 through December 2013. Significant outbreak events and scientific advances during this time period are highlighted below.

Figure 4

Figure 4

Coronavirus phylogeny. Phylogenetic tree of coronaviruses with representatives of each of the four genera; Alpha (pink), Beta (gray), Delta (blue), and Gammacoronavirus (yellow). Betacoronaviruses are further subdivided into clades A through D, with clade B (green) containing

SARS

‐CoV and clade C (orange) containing

MERS

‐CoV. All known human coronaviruses are represented in red. Maximum‐likelihood trees were generated with the

MEGA

5 software package using a 1231‐nucleotide segment within the RdRp. Trees were visualized using Figtree. Bootstrap values above 75 are shown. CoV isolation origin abbreviations as follows: H: human; Bt: bat; Bt

SL

: bat

SARS

‐like;

BW

: beluga whale;

IBV

: chicken;

FIPV

: feline;

TGEV

: swine; M: mink;

MHV

: murine; Th: thrush; Bu: bulbul; Mun: munia.

Figure 5

Figure 5

Putative

MERS

‐CoV transmission cycle. The putative transmission cycle for

MERS

‐CoV.

MERS

‐CoV likely originated from bats, acting as the natural reservoir. From the natural reservoir,

MERS

‐CoV spilled either directly over to humans (green arrow) or via an intermediate host (dromedary camels, purple arrow). Currently, the exact route of zoonotic transmission of

MERS

‐CoV into the human population remains unknown although the presence of

MERS

‐CoV neutralizing antibodies and the detection of

MERS

‐CoV in dromedary camels suggest that this species is likely to play a major role in the emergence of

MERS

‐CoV. Phylogenetic analysis suggests that multiple introductions of

MERS

‐CoV into the human population have occurred and both zoonotic transmission events and human‐to‐human transmission (blue arrows) drive the current

MERS

‐CoV outbreak.

Figure 6

Figure 6

MERS

‐CoV spike glycoprotein and

DPP

4 receptor interaction. (a) The linear organization of the S1 subunit of

MERS

‐CoV spike glycoprotein with the variable

RBD

located at amino acid residues 367–607, with a

RBM

containing the critical amino acid residues for binding at residues 484–567. (b) The crystal structure of the

MERS

‐CoV

RBD

coupled with the receptor dipeptidyl peptidase

IV

(

DPP

4).

DPP

4 is structurally divided into an alpha‐ and beta‐hydrolase domain, and a beta‐propeller domain. The beta‐propeller domain of

DPP

4 (pink) interacts with the

RBM

region (light blue) of the

MERS

‐CoV spike protein

RBD

. The schematic representation of the

DPP

4 –

MERS

‐CoV spike protein

RBD

structure was generated using chimera and protein accession number 4

KR

0 (Lu et al., 2013).

Figure 7

Figure 7

Geographic distribution of dromedary camels. The global distribution of dromedary camels is indicated by yellow shading (Mukasa‐Mugerwa, 1981).

Similar articles

Cited by

References

    1. Agnihothram S, Gopal R, Yount B et al (2013) Platform strategies for rapid response against emerging coronaviruses: MERS‐CoV serologic and antigenic relationships in vaccine design. J Infect Dis [Epub ahead of print]. - PMC - PubMed
    1. Albarrak A, Stephens G, Hewson R & Memish Z (2012) Recovery from severe novel coronavirus infection. Saudi Med J 33: 1265–1269. - PubMed
    1. Al‐Daghri N, Al‐Attas O, Alokail M, Alkharfy K, Yousef M, Sabico S & Chrousos G (2011) Diabetes mellitus type 2 and other chronic non‐communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic. BMC Med 9: 76. - PMC - PubMed
    1. Almazán F, Dediego M, Sola I et al (2013) Engineering a replication‐competent, propagation‐defective Middle East Respiratory Syndrome coronavirus as a vaccine candidate. mBio 4: e00650–13. - PMC - PubMed
    1. Annan A, Baldwin H, Corman V et al (2013) Human betacoronavirus 2c EMC/2012‐related viruses in bats, Ghana and Europe. Emerg Infect Dis 19: 456–459. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources